GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:003105614 | Esophagus | ESCC | regulation of histone modification | 106/8552 | 152/18723 | 1.52e-09 | 3.55e-08 | 106 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00310583 | Esophagus | ESCC | positive regulation of histone modification | 65/8552 | 92/18723 | 1.04e-06 | 1.31e-05 | 65 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:20007564 | Esophagus | ESCC | regulation of peptidyl-lysine acetylation | 43/8552 | 63/18723 | 2.43e-04 | 1.50e-03 | 43 |
GO:00510926 | Esophagus | ESCC | positive regulation of NF-kappaB transcription factor activity | 91/8552 | 152/18723 | 2.91e-04 | 1.75e-03 | 91 |
GO:19019835 | Esophagus | ESCC | regulation of protein acetylation | 49/8552 | 77/18723 | 1.12e-03 | 5.60e-03 | 49 |
GO:00350653 | Esophagus | ESCC | regulation of histone acetylation | 36/8552 | 54/18723 | 1.49e-03 | 7.06e-03 | 36 |
GO:00165721 | Esophagus | ESCC | histone phosphorylation | 27/8552 | 39/18723 | 2.52e-03 | 1.08e-02 | 27 |
GO:00331271 | Esophagus | ESCC | regulation of histone phosphorylation | 10/8552 | 12/18723 | 8.94e-03 | 3.12e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS6KA4 | SNV | Missense_Mutation | novel | c.461N>C | p.Lys154Thr | p.K154T | O75676 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS6KA4 | SNV | Missense_Mutation | novel | c.1931N>T | p.Ser644Phe | p.S644F | O75676 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS6KA4 | SNV | Missense_Mutation | rs755246792 | c.758G>A | p.Arg253Gln | p.R253Q | O75676 | protein_coding | deleterious(0.04) | possibly_damaging(0.904) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA4 | SNV | Missense_Mutation | rs200299338 | c.887G>A | p.Arg296Gln | p.R296Q | O75676 | protein_coding | deleterious(0) | benign(0.082) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPS6KA4 | SNV | Missense_Mutation | novel | c.1000N>A | p.Glu334Lys | p.E334K | O75676 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
RPS6KA4 | SNV | Missense_Mutation | rs779918376 | c.791G>A | p.Arg264Gln | p.R264Q | O75676 | protein_coding | tolerated(0.69) | benign(0) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPS6KA4 | SNV | Missense_Mutation | novel | c.1117G>A | p.Ala373Thr | p.A373T | O75676 | protein_coding | tolerated(0.14) | possibly_damaging(0.455) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
RPS6KA4 | SNV | Missense_Mutation | novel | c.535G>A | p.Asp179Asn | p.D179N | O75676 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RPS6KA4 | SNV | Missense_Mutation | rs111697527 | c.2225N>T | p.Arg742Leu | p.R742L | O75676 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-CC-A8HT-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
RPS6KA4 | SNV | Missense_Mutation | | c.439N>A | p.Leu147Met | p.L147M | O75676 | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-DD-A3A2-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8986 | RPS6KA4 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE, ENZYME | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
8986 | RPS6KA4 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE, ENZYME | inhibitor | 252827421 | | |
8986 | RPS6KA4 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE, ENZYME | | LINIFANIB | LINIFANIB | |